Clinical trial
A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
NCT00485836 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared With Sham in Subjects With Macular Edema Secondary to Central Retinal Vein Occlusion
- Lead sponsor
- Genentech, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- July 31, 2007
- Completion date
- December 31, 2009
- Enrollment
- 392 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.